In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 318 for your search:

Drug:  erlotinib hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO18109, NCT00949910

A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer

Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ML20569, NCT01066884

TAilored Post-Surgical Therapy in Early Stage NSCLC

Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: IFCT-0801, Eudract : 2008-004939-38, NCT00775385

Phase III Randomized Study of Carboplatin and Paclitaxel With or Without Erlotinib (Tarceva) in Patients With Chemotherapy Naive Stage IIIB or IV Non-Small Cell Lung Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENENTECH-OSI2298g, MSKCC-01122, NCT00029016

Phase III Randomized Study of Whole Brain Radiotherapy and Stereotactic Radiosurgery With Versus Without Temozolomide or Erlotinib in Patients With Non-Small Cell Lung Cancer and Brain Metastases

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: RTOG-0320, NCT00096265

A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI3199g, NCT00091663

A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI3364g, NCT00130728

Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: D-0410, NCT00153803

Combination Chemotherapy and Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CDR0000453861, GERCOR-C04-2, EU-20565, GERCOR-OPTIMOX3-TARCEVA, ROCHE-GERCOR-C04-2, GERCOR-DREAM- C04-2, NCT00265824

10.

Erlotinib or Observation in Treating Patients Who Have Undergone First-Line Chemotherapy for Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer

Phase: Phase III
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other
Protocol IDs: CDR0000455566, EORTC-55041, EUDRACT-2004-004333-34, NCT00263822

11.

Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Phase: Phase III
Type: Health services research, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000457755, LLCG-TOPICAL, EU-20313, ISRCTN, Cancer Research UK (CTAAC), Roche AG Pharma, UCL Trial Sponsor reference, EudraCT number, ISRCTN77383050, NCT00275132

12.

A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AVF3671g, NCT00257608

13.

Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)

Phase: Phase III
Type: Treatment
Status: Completed
Age: 75 to 90
Sponsor: Other
Protocol IDs: IFCT-0501, NCT00298415

14.

IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2005.386, NCT00300586

15.

Phase III Randomized Study of Prophylactic Topical Sunscreen for the Prevention of Erlotinib-, Cetuximab-, or Other Epidermal Growth Factor Receptor Inhibitor-Induced Skin Rash in Patients With Cancer

Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N05C4, N05C4, NCCTG N05C4, NCT00362986

16.

TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over; 18 to 70 in Italy
Sponsor: Other
Protocol IDs: TORCH, 2005-005968-90, NCT00349219

17.

Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D4200C00057, EUDRACT No. 2006-000259-16, NCT00364351

18.

A Study of Tarceva After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSI-774-302, 2005-001747-29, NCT00373425

19.

Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: RC-57 crossover, NCT00440167

20.

Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)

Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CT/06.05, NCT00440414

21.

A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181087, SUN1087, NCT00457392

22.

Erlotinib Prevention of Oral Cancer (EPOC)

Phase: Phase III
Type: Prevention
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2003-0824, EPOC, P01CA106451, NCT00402779

23.

A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO18602, NCT00556322

24.

A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO18192, NCT00556712

25.

Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva